Table 2.
Cardiovascular outcome trials with DPP4 inhibitors.
| DPP4i | Trial (Year) | Median Follow-Up, Years |
Mean/Median Age, Years |
Female (Total) | BMI, kg/m2 * | HbA1c, mmol/mol (%) * | Baseline Metformin, % |
Baseline eGFR, mL/min/ [1.73 m]2 * |
Prior ASCVD, % |
Prior CHF, % |
|---|---|---|---|---|---|---|---|---|---|---|
| Sitagliptin | TECOS (2015) | 3.0 | 65 | 4212 | 30.2 | 55 (7.2) | 81 | 75 | 100 | 18 |
| (14,523) | ||||||||||
| Saxagliptin | SAVOR-TIMI (2013) | 2.1 | 65 | 5590 | 31.2 | 64 (8.0) | 69 | 73 | 78 | 13 |
| (16,492) | ||||||||||
| Alogliptin | EXAMINE (2013) | 1.5 | 61 | 1722 | 28.7 | 64 (8.0) | NA | 71 | 100 | 28 |
| (5380) | ||||||||||
| Linagliptin | CARMEL (2019) | 2.2 | 66 | 2582 | 31.4 | 64 (8.0) | 54 | 55 | 57 | 27 |
| (6979) |
NA, not available; * These are expressed as mean values.